Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02786901 · ClinicalTrials.gov registry record · Phase 3
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT02786901: Completed Phase 3 study, sponsored by Bausch & Lomb Incorporated.
NCT02786901 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 600 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02786901, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
Primary Outcome
Slit lamp examination was performed. White blood cell accumulation in anterior aqueous humor was assessed by the Investigator during slit lamp examination and graded on a 5-point scale: Grade 0 = no cells seen; Grade 1 = 1 to 5 cells; Grade 2 = 6 to 15 cells; Grade 3 = 16 to 30 cells; Grade 4 = \> 30 cells. Complete resolution of AC cells was defined as Cell score = 0 in the study eye.
Interventions
- DRUG Vehicle Gel
- DRUG Loteprednol Etabonate Ophthalmic Gel dosed TID
- DRUG Loteprednol Etabonate Ophthalmic Gel dosed BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-07-01 |
| Phase | Phase 3 |
What the finished NCT02786901 record still lists
NCT02786901 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 3 interventions - of which Vehicle Gel is the first listed.
NCT02786901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02786901 about?
NCT02786901 is a clinical study titled "LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
What is the current status of trial NCT02786901?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2016-06. Estimated completion is 2017-07-01.
What interventions are being tested in trial NCT02786901?
The interventions under investigation include: Vehicle Gel (DRUG), Loteprednol Etabonate Ophthalmic Gel dosed TID (DRUG), Loteprednol Etabonate Ophthalmic Gel dosed BID (DRUG).
Who is sponsoring clinical trial NCT02786901?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02786901's enrollment target sits among peer trials
600 608th of 2000 higher than 1,363 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia